Whitelaw A, Kennedy C R, Brion L P
Division of Child Health, University of Bristol, Division of Child Health, Southmead Hospital, Bristol, UK, BS10 5NB.
Cochrane Database Syst Rev. 2001;2001(2):CD002270. doi: 10.1002/14651858.CD002270.
Intraventricular hemorrhage remains a serious complication of premature birth and post hemorrhagic hydrocephalus still has no satisfactory treatment. Acetazolamide and furosemide, which both reduce the production of cerebrospinal fluid, have been suggested as non-invasive therapies to reduce hydrocephalus and the need for ventriculo-peritoneal (V-P) shunting.
The aim of this review was to determine whether the use of acetazolamide and furosemide improves outcome, especially shunt dependence, in infants developing post-hemorrhagic ventricular dilatation.
The standard search strategy of the Cochrane Collaboration was used.
Randomised, or quasi-randomised trials, of acetazolamide and/or furosemide compared with standard therapy in infants with IVH or post-hemorrhagic ventricular dilatation
Data were extracted independently by each author and were analysed by the standard methods of the Cochrane Collaboration using relative risk (RR) and risk difference (RD), a fixed effect model and sensitivity analyses where appropriate.
There were two eligible trials: one randomized 16 infants and the other, 177. Neither showed a decreased risk for V-P shunt or for V-P shunt or death associated with acetazolamide and furosemide therapy. The larger trial showed that acetazolamide and furosemide treatment resulted in a borderline increase in the risk for motor impairment at one year (RR 1.27, CI 1.02 to 1.58; RD 0.16, CI 0.02 to 0.31), but did not significantly affect the risk for the combined outcome of delay, disability or motor impairment among survivors, or the risk of the combined outcome of death, delay, disability or impairment at one year. The larger trial showed that diuretic treatment increased the risk for nephrocalcinosis (RR 5.31, CI 1.90 to 14.84; RD 0.19, CI 0.09 to 0.29); meta-analysis confirmed this result.
REVIEWER'S CONCLUSIONS: Acetazolamide and furosemide therapy is neither effective nor safe in treating post hemorrhagic ventricular dilatation. Acetazolamide and furosemide cannot be recommended as therapy for post hemorrhagic hydrocephalus.
脑室内出血仍然是早产的一种严重并发症,出血后脑积水仍没有令人满意的治疗方法。乙酰唑胺和呋塞米都能减少脑脊液生成,已被建议作为减少脑积水和脑室腹腔分流术需求的非侵入性治疗方法。
本综述的目的是确定使用乙酰唑胺和呋塞米是否能改善出血后脑室扩张婴儿的预后,尤其是分流依赖情况。
采用Cochrane协作网的标准检索策略。
将乙酰唑胺和/或呋塞米与标准治疗方法进行比较的随机或半随机试验,受试对象为患有脑室内出血或出血后脑室扩张的婴儿。
每位作者独立提取数据,并采用Cochrane协作网的标准方法,使用相对危险度(RR)和危险度差值(RD)、固定效应模型以及在适当情况下进行敏感性分析。
有两项符合条件的试验:一项试验纳入了16名婴儿,另一项试验纳入了177名婴儿。两项试验均未显示乙酰唑胺和呋塞米治疗能降低脑室腹腔分流术的风险,或降低与脑室腹腔分流术或死亡相关的风险。规模较大的试验表明,乙酰唑胺和呋塞米治疗导致1岁时运动障碍风险有临界性增加(RR 1.27,CI 1.02至1.58;RD 0.16,CI 0.02至0.31),但对幸存者中延迟、残疾或运动障碍联合结局的风险,或1岁时死亡、延迟、残疾或损伤联合结局的风险没有显著影响。规模较大的试验表明,利尿剂治疗增加了肾钙质沉着症的风险(RR 5.31,CI 1.90至14.84;RD 0.19,CI 0.09至0.29);荟萃分析证实了这一结果。
乙酰唑胺和呋塞米治疗在治疗出血后脑室扩张方面既无效也不安全。不推荐将乙酰唑胺和呋塞米作为出血后脑积水的治疗方法。